Kelly Close
PresidentClose Concerns
Kelly Close is Founder and President of Close Concerns, a healthcare information firm focused exclusively on diabetes and obesity. She has over 15 years of experience at the intersection of finance and healthcare. Ms. Close specializes in financial analysis and marketing within the diabetes and obesity industries. She provides advisory services on topics related to pharmaceutical, medical device, and biotechnology products for diabetes and is a frequent speaker and writer in this field. Before starting Close Concerns, Ms. Close worked at Goldman Sachs, McKinsey & Company and in the medical device equity research teams at Merrill Lynch and Piper Jaffray. She is the Editor-in-Chief of Diabetes Close Up, an industry newsletter, and diaTribe, a patient newsletter on research and new products in the field. She has an extensive patient database and stays up to date on patient interests in these fields. (This is me - Update Profile)
| 2002 - present | President Close Concerns |
|---|---|
| 2000 - 2002 | Research Analyst Piper Jaffray |
| 1995 - 1998 | Associate McKinsey & Co. |
| 1990 - 1993 | Analyst Goldman Sachs |
GLG Study Groups with Kelly Close(?)
| Study Group Name | Members |
|---|---|
| Physicians who Treat Diabetes (US) | 425 |
| DexCom's Continuous Glucose Monitoring System Experts | 24 |
| DexCom Continuous Glucose Monitoring Systems Users | 20 |
GLG NewsSM Analyses by Kelly Close(?)
This was a great NYT story. The fact that Byetta was suggested as cardioprotective out of ACCORD was truly ignored by the media and nice to see the suggestion here. FDA is moving much more this direction and from a patient perspective, having a cardioprotective drug (LAR) that is easier to take...
Galvus was not approved in a once per day 100 mg version for Europe, which puts it as a disadvantage to Merck's Januvia. To boot, there are liver testing requirements that will also be a drag.
GLG InstituteSM Seminars with Kelly Close(?)
Recent Seminars
Request a project with Kelly Close
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms